TCBP News and Press, TC BioPharm (Holdings) plc From 12/12/22

TC Biopharm press release ( NASDAQ: TCBP ): 1H GAAP EPS of $1.13. Revenue of $1.2M. Cash and cash equivalents were £6.0 million or $7.3 million as of June 30, 2022 compared to £1.6 million as of December 31, 2021. For further details see: TC Biopharm GAAP E...

TC BioPharm Reports First Half 2022 Financial Results and Provides Shareholder Update PR Newswire Dosed first three patients within Phase 2b clinical trial of OmnImmune®, an allogeneic unmodified cell therapy focused on treating Acute Myeloid Leukemia (AML). ...

TC BioPharm Announces Closing of $7.35 Million Private Placement PR Newswire EDINBURGH, Scotland , Nov. 30, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (Nasdaq: TCBP) (Nasdaq: TCBPW), a clinical stage biotechnology company dev...

TC BioPharm Announces $7.35 Million Private Placement PR Newswire EDINBURGH, Scotland , Nov. 28, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (Nasdaq: TCBP) (Nasdaq: TCBPW), a clinical stage biotechnology company d...

TC BioPharm Begins Dosing Phase 2B Clinical Study Evaluating its Lead Compound, OmnImmune®, in Patients with Acute Myeloid Leukemia PR Newswire 3 Patients Dosed in 5 Patient Safety Cohort EDINBURGH, Scotland , Nov. 22, 2022 /PRNewswire/ -...

TC BioPharm Announces Key Additions to Scientific Advisory Board, Expanding Cell Therapy Expertise PR Newswire SAB selected to advance new therapeutic trials and strategic partnerships EDINBURGH, Scotland , Oct. 26, 2022 /PRNewswire/ -- TC Bi...

TC BioPharm to Present at Upcoming Investor Conferences PR Newswire EDINBURGH, Scotland , Oct. 3, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company devel...

TC BioPharm Receives MHRA Approval for 18-Month Extrapolated Shelf-Life of Allogeneic Cell Therapy Product, OmnImmune® PR Newswire EDINBURGH, Scotland , Sept. 13, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDA...

TC BioPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire EDINBURGH, Scotland , Aug. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical s...

TC BioPharm Executives to Speak at The 3rd Gamma Delta T Therapies Summit PR Newswire Event Taking Place in Boston on July 26-28, 2022 EDINBURGH, Scotland , July 25, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Co...